Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Evanthia Bernitsas
 -- 1944 2024-01-19 18:38:44 |
2 format change
Peter Tang
Meta information modification 1944 2024-01-22 03:29:07 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Elkhooly, M.; Bao, F.; Bernitsas, E. Oral Disease Modifying Therapy on Multiple Sclerosis-Related Fatigue. Encyclopedia. Available online: https://encyclopedia.pub/entry/54134 (accessed on 06 July 2024).
Elkhooly M, Bao F, Bernitsas E. Oral Disease Modifying Therapy on Multiple Sclerosis-Related Fatigue. Encyclopedia. Available at: https://encyclopedia.pub/entry/54134. Accessed July 06, 2024.
Elkhooly, Mahmoud, Fen Bao, Evanthia Bernitsas. "Oral Disease Modifying Therapy on Multiple Sclerosis-Related Fatigue" Encyclopedia, https://encyclopedia.pub/entry/54134 (accessed July 06, 2024).
Elkhooly, M., Bao, F., & Bernitsas, E. (2024, January 19). Oral Disease Modifying Therapy on Multiple Sclerosis-Related Fatigue. In Encyclopedia. https://encyclopedia.pub/entry/54134
Elkhooly, Mahmoud, et al. "Oral Disease Modifying Therapy on Multiple Sclerosis-Related Fatigue." Encyclopedia. Web. 19 January, 2024.
Oral Disease Modifying Therapy on Multiple Sclerosis-Related Fatigue
Edit
This entry is adapted from the peer-reviewed paper 10.3390/brainsci14010004

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system by causing inflammation, demyelination and neurodegeneration. Fatigue is the most prevalent and one of the most disabling symptoms among people with MS (pwMS). Due to its complexity and subjective character, fatigue is still little understood despite its frequent occurrence and severe impact.

multiple sclerosis fatigue disease modifying therapies

1. Introduction

One of the most prevalent and disabling signs of multiple sclerosis (MS) is fatigue, which has been linked to a lower quality of life [1][2][3]. Little is understood about the fundamental reason, despite its relevance. Numerous pharmacological and non-pharmacological modalities have been researched, but there are limited data to support their efficacy [4][5]. It was proposed that peripheral or central inflammation could be the root of fatigue [6].
Fatigue severity is self-reported. Over the years, several imaging biomarkers have been identified in an attempt to associate the subjective nature of fatigue with objective measures [7][8][9].
Fatigue remains a significant issue for most MS patients and along with depression is closely correlated with the quality of life in the MS patients [10]. Given that the pathophysiology of MS-related fatigue may involve neuroinflammation, it is reasonable to hypothesize that the DMTs with their well-known anti-inflammatory action may potentially ameliorate fatigue. However, it is unknown how these drugs affect fatigue because the duration of fatigue was not examined in randomized, prospective trials [7][8][9].

2. Fatigue and Rating Scales

Different scales have been used to measure fatigue severity. The modified fatigue impact scale (MFIS) is a modified version of the 40-item Fatigue Impact Scale (FIS), which was developed initially to evaluate how fatigue affects people with chronic diseases, notably MS, in terms of quality of life. A questionnaire containing 10 “physical” questions, 10 “cognitive” items, and 20 “social” items is used by FIS patients to score how much tiredness has interfered with their lives over the previous four weeks, with 0 denoting “no problem” and 4 denoting “severely affected”. Maximum score is 160 [1][11]. Nine “physical” items, ten “cognitive” items, and two “psycho-social” elements make up the MFIS. Higher ratings indicate a stronger influence on quality of life, with a maximum score of 84. Another scale is FSS, which was created by Krupp in 1989; it is a self-reported scale that assesses the level of fatigue. FSS contains nine items. The patient is asked to select a number between 1 and 7, where 1 denotes strong disagreement and 7 denotes strong agreement to represent how strongly the patient agrees or disagrees with each statement in each question. Severe fatigue is typically indicated by a score of 4 or higher [3].
The Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis (FSIQ-RMS-S) is another scale for MS fatigue severity measurement. Seven questions make up the FSIQ-RMS-S, which measures symptoms of fatigue during the preceding 24 h. Physical weakness, mental exhaustion, physical fatigue, energy, feeling worn out, feeling sleepy, and feeling worn out while at rest are the things listed. On an 11-point numerical rating scale (NRS), from 0 (no symptoms) to 10, respondents are asked to score each item (highest level of symptoms). Individual item scores are added together to produce an FSIQ-RMS-S score that ranges from 0 to 70 and is then rescaled to range from 0 to 100. More serious fatigue is indicated by a higher FSIQ-RMS-S score [12].

3. MS Therapies

The most typical technique to monitor MS disease progression is through routine clinical evaluations and MRI scans. It is crucial to keep track of these metrics in order to assess whether and how well a patient’s DMT is controlling their MS. For MS patients, a range of DMTs are currently available. The various administration methods, action and effect of different DMTs on fatigue are shown in Table 1 and Table 2.
Table 1. FDA-approved DMT and their methods of administration. DMT: Disease Modifying Therapies.

Oral DMTs

Infusion DMTs

Injectable DMTs

Dimethyl fumarate

Natalizumab

Glatiramer acetate

Sphingosine 1-P modulators (Fingolimode, Siponimod, Ponesimod, Ozanimod)

Alemtuzumab

Interferons

Teriflunomide

Ocrelizumab

Ofatumumab

Cladribine

Mitoxantrone

  
Table 2. Summary of various FDA-approved DMTs, mechanism of action and their effect on fatigue. SPMS: secondary progressive MS, PRMS: progressive relapsing MS, RRMS: relapsing remitting MS, CIS: clinically isolated syndrome, DMTs: disease modifying therapies. * 21 is the main study while 22 is a post hoc analysis. ** 40 showed mixed results.

DMT

Approved Indication

Mechanism of Action

Studies with Positive Impact on Fatigue

Studies with Negative Impact on Fatigue

Studies with No Impact on Fatigue

Dimethyl fumarate

CIS, RRMS

Activates the nuclear factor erythroid 2 related factor 2 (Nrf2) transcriptional pathway.

[13][14][15][16]

  

[17][18][19]

Fingolimod

CIS, RRMS

Sphingosine 1 phosphate receptor

[20][21][22] *

[23][24][25][26][27]

[28]

Siponimod

CIS, RRMS, active SPMS

Sphingosine 1 phosphate receptor

  

[29]

[30]

Ponesimod

CIS, RRMS

Sphingosine 1 phosphate receptor

OPTIMUM [31]

    

Teriflunomide

CIS, RRMS

Mitochondrial dihydro-orotate dehydrogenase (DHODH) inhibitor

TENERE [32][33]

[34]

Teri-Fast [35]

Cladribine

CIS, active SPMS

Lymphocyte depletion

[36]

    

Glatiramer acetate (GA)

CIS, RRMS

Anti-inflammatory

[37][38][39][40][41][42] **

  

[43][44]

Interferons

CIS, RRMS

Anti-inflammatory

[45][46]

[47]

  

Alemtuzumab

Aggressive RRMS

Anti- CD20

[48]

    

Mitoxantrone

RRMS, SPMS, PRMS

Type II Topoisomerase inhibitor

  

[49]

  

Natalizumab

RRMS

Interfere with t cell transmigration

[50][51][52][53][54][55]

[56]

[57]

Ocrelizumab

RRMS,

SPMS

Anti-CD20

[58]

    

4. Oral DMTs

4.1. Dimethyl Fumarate (Tecfidera)

Dimethyl fumarate (DMF) is an FDA-approved drug for relapsing forms of MS (RRMS, CIS and SPMS). DMF activates the erythroid-derived nuclear factor, a defense system against oxidative and inflammatory stress [59].
Several previous studies explore the effect of DMF on fatigue. A large prospective 12-month observational study (RESPOND) on 318 RRMS patients who switched from glatiramer acetate (GA) to DMF showed marked improvement in MFIS on DMF, from 10.7 (5.2) at baseline to 9.3 (5.2) after 12 months (mean change 0.83 [3.51]; p = 0.0002) [13].
A smaller prospective study of 24 month duration on 34 RRMS patients showed that at 3, 6, 12, and 24 months following DMF treatment, MFIS scores were considerably reduced (7.85 ± 12.20, p < 0.01; 7.75 ± 15.59, p < 0.01; 8.40 ± 15.55, p < 0.001; 10.25 ± 10.92, p = 0.0001) [16]. Amato et al. confirmed the previous results in reduction in MFIS score over 24 months among 165 RRM patients (least square mean (LSM) difference: −3.526, 95% CI: −4.782 to −2.271; p < 0.001) [15]. Additionally, the PROTEC study showed that 867 of 1105 RRMS patients treated with DMTs showed marked improvement in MFIS [14].
MFIS-5 remained stable over a 12-month period of DMF treatment in the ESTEEM trial involving 2025 RRMS patients [18].
In a retrospective small sample study by Pandey et al. failed to show any improvement in self-reported fatigue in DMT-treated patients especially when it co-exists with depression [19].
Comi and colleagues investigated the effect of DMF on sleep quality on 223 RRMS over 48 weeks (177 RRMS on DMF, 46 RRMS on interferon). The study explored fatigue as a secondary end point using the FSS. Despite the subjective self-reported improvement in fatigue due to significant positive effect on sleep quality, the study failed to demonstrate significant changes in fatigue, mobility or quality of life over the study duration [17].

4.2. Sphinosine-1—Phosphate Modulators

4.2.1. Fingolimod

Fingolimod is an FDA-approved DMT for CIS and RRMS also marketed as Gilenya. It has distinct immunoregulatory characteristics and affects sphingosine-1-phosphate receptors. Fingolimod stops immune cells from leaving lymphoid tissue and reaching the inflammatory tissue [60].
There are limited studies which evaluate the impact of fingolimod on fatigue. Masinque’s earlier prospective open label trial on 54 RRMS patients found no improvement in the MFIS-measured fatigue score and FSS at a 6-month interval [28].
In contrast, another study compared the effect of fingolimod with that of the injectable DMT among 1053 RRMS patients, which showed that marked improvement in FSS in the fingolimod group who received it at least 6 months after switch from injectable DMT [21][22][61]. This can be better explained by a lower mean of EDSS (2.5 versus 2.7) in Masingue’s study. The Hamburg Quality of Life Questionnaire in MS (HAQUAMS) was administered to 281 patients who were randomly assigned to take oral fingolimod (n = 188) or a placebo (n = 93). With fingolimod, the overall HAQUAMS score improved, while with placebo, it worsened. The mean score changed by 0.02 with fingolimod 1.25 mg (p < 0.05 against placebo), 0.01 with fingolimod 5.0 mg, and 0.12 with placebo from baseline to month six. Additionally, fingolimod 1.25 mg was superior to placebo in the HAQUAMS sub-domain for fatigue/thinking (p < 0.05 vs. placebo) [20]. As a side effect, all groups in FREEDOMS and TRANSFORMS experienced documented adverse events at a similar rate. Fatigue and headache were among the side effects that occurred in the fingolimod groups and affected approximately 10% of participants [26][27]. In another trial, 24 (19.7%) of the 122 patients receiving fingolimod had fatigue [25]. This was confirmed by another study conducted by Rojas [24] who reported that 16 patients of 145 (11%) of fingolimod-treated patients reported fatigue. The same percentage was also reported by Brown et al. [23]. More studies are needed for further exploration to identify patients whose fatigue will benefit from fingolimod versus those who will develop fatigue as a side effect.

4.2.2. Siponimod

Siponimod is also known as Mayzent, an FDA-approved medication for CIS, RRMS and SPMS. Its lipophilic nature makes it capable of crossing the blood–brain barrier and act on sphingosine-1-phosphate. There are limited data on the relation between it and fatigue.
In prior research, the safety of Siponimod has been explored, namely in the EXPAND trial which included 1099 secondary progressive MS patients for more than 5 years. It showed that fatigue may be reported as a side effect of Siponimod use with an incidence rate of 6.3% compared to 6.6% in the placebo group [29]. Hoffman et al. reported that among 1500 patients treated by Siponimod, fatigue and quality of life remained stable after 12 months using MFSC and EQ-5D, respectively [30].

4.2.3. Ponesimod

Ponesimod is a highly selective modulator of sphingosine-1-phosphate receptor 1 (S1P1) with low potential for drug–drug interaction because it is an orally active drug [62]. It also has no active metabolites. Ponesimod prevents lymphocytes from leaving lymphoid organs, which causes a quick, dose-dependent, and reversible decrease in peripheral blood lymphocyte levels [63][64].
Ponesimod was compared with teriflunomide in phase three OPTIMUM study, which included 1133 patients with RRMS. Ponesimod was significantly superior to teriflunomide in reducing fatigue using FSIQ-RRM with a mean score of −3.57 (−0.01 vs. 3.56; p < 0.001) in the ponesimod group [31].

4.2.4. Ozanimod

Ozanimod received FDA- approval in March 2020 to treat RRMS, active SPMS, and CIS. Ozanimod is a sphingosine-1-phosphate receptor (S1PR) modulator and is marketed under the trade name ZEPOSIA. The only S1PR modulator currently approved by the US FDA that does not need genetic testing or first-dose monitoring is Ozanimod, in contrast to earlier medications in its class [65][66]. The first study examined ozanimod on fatigue is the OCEAN study, which is still ongoing in Germany. It aims to include 1300 RRMMS patients over 36 months. Their primary outcomes include patient satisfaction and effectiveness. As a secondary outcome, it also aims to study fatigue and quality of life using FSMC and MSQOL-54, respectively [67].

4.3. Teriflunomide (Aubagio)

The FDA has approved teriflunomide for CIS and RRMS patients. It works by inhibiting mitochondrial dihydro-orotate dehydrogenase (DHODH), which results in less pyrimidine being synthesized, which is essential for the proliferation of lymphocytes. Therefore, the absence of DHODH caused by teriflunomide limits the ability of lymphocytes to attack the neurological system. Previous studies explore its effect on fatigue. A total of 324 individuals were randomly assigned to receive IFN-1a, teriflunomide 7 mg, or teriflunomide 14 mg. FIS scores showed more prominent fatigue in the INF-1a group, though differences were only significant when compared with teriflunomide 7 mg [33]. Additionally, in Teri-Real observational study, which includes 212 patients, the overall FIS score as well as its cognitive and psychosocial components remained stable. After two years, compared to the baseline, the physical component of FIS did exhibit a statistically significant improvement (11.33 vs. 13.09) [32].
Despite having a favorable outcome, Teri-FAST, which was a 2-year, prospective, observational study over 210 patients, confirmed that fatigue remained stable with no significant improvement [35]. Data from TEMSO and TOWER showed that there is an increased fatigue rate especially with relapses leading to hospitalization [34].

4.4. Cladribine

A deoxyadenosine analogue called cladribine is phosphorylated to form human lymphocyte-specific cytotoxin 2-chlorodeoxyadenosine triphosphate [68][69]. A prior two-year study examined how cladribine affected quality of life using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) and the EuroQol five-dimension three-level (EQ-D5-3L)18. Low-dose cladribine 3.5 mg administered to 5148 RRMS patients showed marked improvement using EQ-5D but failed to show any statistical improvement using MSQOL-54 [36]. Further research is needed to reach a definite conclusion.

References

  1. Fisk, J.D.; Ritvo, P.G.; Ross, L.; Haase, D.A.; Marrie, T.J.; Schlech, W.F. Measuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale. Clin. Infect. Dis. 1994, 18 (Suppl. S1), S79–S83.
  2. Freal, J.E.; Kraft, G.H.; Coryell, J.K. Symptomatic fatigue in multiple sclerosis. Arch. Phys. Med. Rehabil. 1984, 65, 135–138.
  3. Krupp, L.B. The Fatigue Severity Scale. Arch. Neurol. 1989, 46, 1121.
  4. Branas, P.; Jordan, R.; Fry-Smith, A.; Burls, A.; Hyde, C. Treatments for fatigue in multiple sclerosis: A rapid and systematic review. Health Technol. Assess. 2000, 4, 1–61.
  5. Giovannoni, G.; Thompson, A.J.; Miller, D.H.; Thompson, E.J. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 2001, 57, 676–681.
  6. Heesen, C.; Nawrath, L.; Reich, C.; Bauer, N.; Schulz, K.H.; Gold, S.M. Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour? J. Neurol. Neurosurg. Psychiatry 2006, 77, 34–39.
  7. Yarraguntla, K.; Seraji-Bozorgzad, N.; Lichtman-Mikol, S.; Razmjou, S.; Bao, F.; Sriwastava, S.; Santiago-Martinez, C.; Khan, O.; Bernitsas, E. Multiple Sclerosis Fatigue: A Longitudinal Structural MRI and Diffusion Tensor Imaging Study. J. Neuroimaging 2018, 28, 650–655.
  8. Bernitsas, E.; Yarraguntla, K.; Bao, F.; Sood, R.; Santiago-Martinez, C.; Govindan, R.; Khan, O.; Seraji-Bozorgzad, N. Structural and Neuronal Integrity Measures of Fatigue Severity in Multiple Sclerosis. Brain Sci. 2017, 7, 102.
  9. Yarraguntla, K.; Bao, F.; Lichtman-Mikol, S.; Razmjou, S.; Santiago-Martinez, C.; Seraji-Bozorgzad, N.; Sriwastava, S.; Bernitsas, E. Characterizing fatigue-related white matter changes in MS: A proton magnetic resonance spectroscopy study. Brain Sci. 2019, 9, 122.
  10. Fricska-Nagy, Z.; Füvesi, J.; Rózsa, C.; Komoly, S.; Jakab, G.; Csépány, T.; Jobbágy, Z.; Lencsés, G.; Vécsei, L.; Bencsik, K. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary. Mult. Scler. Relat. Disord. 2016, 7, 26–32.
  11. Larson, R.D. Psychometric properties of the modified fatigue impact scale. Int. J. MS Care 2013, 15, 15–20.
  12. Hudgens, S.; Schüler, R.; Stokes, J.; Eremenco, S.; Hunsche, E.; Leist, T.P. Development and validation of the FSIQ-RMS: A new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis. Value Health 2019, 22, 453–466.
  13. Kresa-Reahl, K.; Repovic, P.; Robertson, D.; Okwuokenye, M.; Meltzer, L.; Mendoza, J.P. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients with Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Clin. Ther. 2018, 40, 2077–2087.
  14. Berger, T.; Brochet, B.; Brambilla, L.; Giacomini, P.S.; Montalbán, X.; Vasco Salgado, A. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC. Mult. Scler. J.—Exp. Transl. Clin. 2019, 5, 2055217319887191.
  15. Amato, M.P.; Goretti, B.; Morra, V.B.; Gallo, P.; Zaffaroni, M.; Onofrj, M.; Cocco, E.; Borriello, G.; Zipoli, V.; Trojano, M. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurol. Sci. 2020, 41, 3185–3193.
  16. Sejbaek, T.; Nielsen, H.H.; Penner, N.; Plavina, T.; Mendoza, J.P.; Martin, N.A.; Elkjaer, M.L.; Ravnborg, M.H.; Illes, Z. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients. J. Neurol. Neurosurg. Psychiatry 2019, 90, 1324–1330.
  17. Comi, G.; Leocani, L.; Ferini-Strambi, L.; Radaelli, M.; Costa, G.D.; Lanzillo, R.; Lus, G.; Bianchi, V.; Traccis, S.; Capone, F.; et al. Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study. Mult. Scler. J. Exp. Transl. Clin. 2023, 9, 20552173221144228.
  18. Giles, K.; Balashov, K.; Jones, C.C.; Macdonell, R.; Miller, C.; Windsheimer, J. Real-World Efficacy of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM (P3. 2-081); AAN Enterprises: Philadelphia, PA, USA, 2019.
  19. Pandey, K.; Russell-Giller, S.; Mohn, J. A-64Observing Self-Reported Fatigue and Depression Before and After Dimethyl Fumarate Therapy in Multiple Sclerosis. Arch. Clin. Neuropsychol. 2017, 32, 667–765.
  20. Montalban, X.; Comi, G.; O’connor, P.; Gold, S.; de Vera, A.; Eckert, B.; Kappos, L. Oral fingolimod (FTY720) in relapsing multiple sclerosis: Impact on health-related quality of life in a phase II study. Mult. Scler. J. 2011, 17, 1341–1350.
  21. Fox, E.; Edwards, K.; Burch, G.; Wynn, D.R.; LaGanke, C.; Crayton, H.; Hunter, S.F.; Huffman, C.; Kim, E.; Pestreich, L.; et al. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult. Scler. Relat. Disord. 2014, 3, 607–619.
  22. Calkwood, J.; Cree, B.; Crayton, H.; Kantor, D.; Steingo, B.; Barbato, L.; Hashmonay, R.; Agashivala, N.; McCague, K.; Tenenbaum, N.; et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: Post hoc analyses of the EPOC trial. BMC Neurol. 2014, 14, 220.
  23. Brown, B.; Weiss, J.L.; Kolodny, S.; Meng, X.; Williams, I.M.; Osborne, J.A. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic. BMC Neurol. 2019, 19, 287.
  24. Rojas, J.I.; Patrucco, L.; Miguez, J.; Cristiano, E. Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. Clin. Neuropharmacol. 2017, 40, 251–254.
  25. Yamout, B.I.; Zeineddine, M.M.; Tamim, H.; Khoury, S.J. Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East. J. Neuroimmunol. 2015, 289, 93–97.
  26. Kappos, L.; Radue, E.-W.; O’Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N. Engl. J. Med. 2010, 362, 387–401.
  27. Cohen, J.A.; Barkhof, F.; Comi, G.; Hartung, H.-P.; Khatri, B.O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. N. Engl. J. Med. 2010, 362, 402–415.
  28. Masingue, M.; Debs, R.; Maillart, E.; Delvaux, V.; Lubetzki, C.; Vidal, J.-S.; Papeix, C. Fatigue evaluation in fingolimod treated patients: An observational study. Mult. Scler. Relat. Disord. 2017, 14, 8–11.
  29. Cree, B.A.; Arnold, D.L.; Fox, R.J.; Gold, R.; Vermersch, P.; Benedict, R.H.; Bar-Or, A.; Piani-Meier, D.; Rouyrre, N.; Ritter, S.; et al. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Mult. Scler. 2022, 28, 1591–1605.
  30. Hoffmann, O.; Schreiber, H.; Klotz, L.; Weber, M.S.; Rauser, B.; Baufeld, C. AMASIA study: Real World Insights on Siponimod Treated Patients with Secondary Progressive Multiple Sclerosis in Germany. Eur. J. Neurol. 2022, 29, 351.
  31. Kappos, L.; Fox, R.J.; Burcklen, M.; Freedman, M.S.; Havrdová, E.K.; Hennessy, B. Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021, 78, 558–567.
  32. Bencsik, K.; Dobos, E.; Jobbágy, Z.; Birkás, A.J.; Kovács, K.; Sátori, M.; Lencsés, G.; Bartok, G.; Losonczi, E.; Vécsei, L.; et al. Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study. Pharmaceuticals 2022, 15, 598.
  33. Vermersch, P.; Czlonkowska, A.; Grimaldi, L.M.E.; Confavreux, C.; Comi, G.; Kappos, L. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult. Scler. J. 2014, 20, 705–716.
  34. Mäurer, M.; Comi, G.; Freedman, M.S.; Kappos, L.; Olsson, T.P.; Wolinsky, J.S.; Miller, A.E.; Dive-Pouletty, C.; Bozzi, S.; O’connor, P.W. Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life—A post hoc analysis of the TEMSO and TOWER studies. Mult. Scler. Relat. Disord. 2016, 7, 33–40.
  35. De Sèze, J.; Devy, R.; Planque, E.; Delabrousse-Mayoux, J.P.; Vandhuick, O.; Kabir, M.; Gherib, A. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study. Mult. Scler. Relat. Disord. 2021, 47, 102659.
  36. Afolabi, D.; Albor, C.; Zalewski, L.; Altmann, D.R.; Baker, D.; Schmierer, K. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult. Scler. 2018, 24, 1461–1468.
  37. Jongen, P.J.; Lehnick, D.; Koeman, J.; Frequin, S.; Heersema, D.; Kornips, B. Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: An observational multi-center study. J. Neurol. 2014, 261, 1469–1476.
  38. Neuhaus, O.; Köhler, W.; Bergh, F.T.; Kristoferitsch, W.; Faiss, J.; Rosenkranz, T.; Reske, D.; Patejdl, R.; Hartung, H.-P.; Zettl, U.K. Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales but Not on Molecular Markers. Biomolecules 2021, 11, 393.
  39. Jongen, P.J.; Lehnick, D.; Sanders, E.; Seeldrayers, P.; Fredrikson, S.; Andersson, M.; Speck, J. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study. Health Qual. Life Outcomes 2010, 8, 133.
  40. Ziemssen, T.; Hoffman, J.; Apfel, R.; Kern, S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual. Life Outcomes 2008, 6, 67.
  41. Meca-Lallana, J.; Hernández, L.; Caminero, A.B.; Girón, J.M.; Cano-Orgaz, A.; Carcelén-Gadea, M. Fatigue improvement after switching multiple sclerosis treatment from interferon-β to glatiramer acetate in clinical practice. Eur. Neurol. 2016, 76, 40–47.
  42. Metz, L.M.; Patten, S.B.; Archibald, C.J.; Bakker, J.I.; Harris, C.J.; Patry, D.G.; Bell, R.B.; Yeung, M.; Murphy, W.F.; Stoian, C.A.; et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1045–1047.
  43. Ziemssen, T.; Calabrese, P.; Penner, I.K.; Apfel, R. QualiCOP: Real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. J. Neurol. 2016, 263, 784–791.
  44. Putzki, N.; Katsarava, Z.; Vago, S.; Diener, H.C.; Limmroth, V. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients. Eur. Neurol. 2008, 59, 136–142.
  45. Melanson, M.; Grossberndt, A.; Klowak, M.; Leong, C.; Frost, E.E.; Prout, M. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. Int. J. Neurosci. 2010, 120, 631–640.
  46. Benešová, Y.; Tvaroh, A. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: An observational study SKORE. Ther. Adv. Neurol. Disord. 2017, 10, 18–32.
  47. Malik, U.R.; Makower, D.F.; Wadler, S. Interferon-mediated fatigue. Cancer 2001, 92, 1664–1668.
  48. Wray, S.; Jacques, F.; Miller, T.A.; Nicholas, J.A.; Arroyo, R.; Travis, L.; Khatri, B.; Chirieac, M.; Gandhi, R.; Roesch, N.; et al. Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study. Mult. Scler. J. Exp. Transl. Clin. 2022, 8, 20552173221135890.
  49. Fox, E.J. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin. Ther. 2006, 28, 461–474.
  50. Putzki, N.; Yaldizli, Ö.; Tettenborn, B.; Diener, H.C. Multiple sclerosis associated fatigue during natalizumab treatment. J. Neurol. Sci. 2009, 285, 109–113.
  51. Penner, I.K.; Sivertsdotter, E.C.; Celius, E.G.; Fuchs, S.; Schreiber, K.; Berkö, S.; Svenningsson, A. Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. Front. Neurol. 2015, 6, 18.
  52. Planche, V.; Moisset, X.; Morello, R.; Dumont, E.; Gibelin, M.; Charré-Morin, J.; Saubusse, A.; Mondou, A.; Reuter, F.; Defer, G.; et al. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study. J. Neurol. Sci. 2017, 382, 148–154.
  53. Svenningsson, A.; Falk, E.; Celius, E.G.; Fuchs, S.; Schreiber, K.; Berkö, S.; Sun, J.; Penner, I.-K. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS ONE 2013, 8, e58643.
  54. Yildiz, M.; Tettenborn, B.; Putzki, N. Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate. Eur. Neurol. 2011, 65, 231–232.
  55. Iaffaldano, P.; Viterbo, R.G.; Paolicelli, D.; Lucchese, G.; Portaccio, E.; Goretti, B.; Direnzo, V.; D’Onghia, M.; Zoccolella, S.; Amato, M.P.; et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: A prospective, open-label, two years observational study. PLoS ONE 2012, 7, e35843.
  56. Yildiz, M.; Tettenborn, B.; Borgwardt, S. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients. Clin. Neurol. Neurosurg. 2013, 115, 902–903.
  57. Kunkel, A.; Fischer, M.; Faiss, J.; Dähne, D.; Köhler, W.; Faiss, J.H. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Front. Neurol. 2015, 6, 97.
  58. Glanz, B.I.; Zurawski, J.; Casady, E.C.; Shamah, R.; Weiner, M.; Chitnis, T.; Weiner, H.L.; Healy, B.C. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Mult. Scler. J. Exp. Transl. Clin. 2021, 7, 20552173211007524.
  59. Xu, Z.; Zhang, F.; Sun, F.; Gu, K.; Dong, S.; He, D. Dimethyl fumarate for multiple sclerosis. In Cochrane Database of Systematic Reviews; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2014.
  60. Ingwersen, J.; Aktas, O.; Kuery, P.; Kieseier, B.; Boyko, A.; Hartung, H.P. Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clin. Immunol. 2012, 142, 15–24.
  61. Druart, C.; El Sankari, S.; van Pesch, V. Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. Patient Relat. Outcome Meas. 2017, 9, 1–10.
  62. D’Ambrosio, D.; Freedman, M.S.; Prinz, J. Ponesimod, a selective S1P1 receptor modulator: A potential treatment for multiple sclerosis and other immune-mediated diseases. Ther. Adv. Chronic Dis. 2016, 7, 18–33.
  63. Piali, L.; Froidevaux, S.; Hess, P.; Nayler, O.; Bolli, M.H.; Schlosser, E.; Kohl, C.; Steiner, B.; Clozel, M. The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation. J. Pharmacol. Exp. Ther. 2011, 337, 547–556.
  64. Chun, J.; Hla, T.; Lynch, K.R.; Spiegel, S.; Moolenaar, W.H. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 2010, 62, 579–587.
  65. Lamb, Y.N. Ozanimod: First Approval. Drugs 2020, 80, 841–848.
  66. T-Cells, C.A.R. US Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (Ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis. Available online: https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1/default.aspx (accessed on 15 November 2023).
  67. Ziemssen, T.; Richter, S.; Mäurer, M.; Buttmann, M.; Kreusel, B.; Poehler, A.-M.; Lampl, M.; Linker, R.A. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients with Relapsing-Remitting Multiple Sclerosis in Germany. Front. Neurol. 2022, 13, 913616.
  68. Warnke, C.; Leussink, V.I.; Goebels, N.; Aktas, O.; Boyko, A.; Kieseier, B.C.; Hartung, H.-P. Cladribine as a therapeutic option in multiple sclerosis. Clin. Immunol. 2012, 142, 68–75.
  69. Giovannoni, G.; Comi, G.; Cook, S.; Rammohan, K.; Rieckmann, P.; Sørensen, P.S.; Vermersch, P.; Chang, P.; Hamlett, A.; Musch, B.; et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N. Engl. J. Med. 2010, 362, 416–426.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mahmoud Elkhooly
,
Fen Bao
,
Evanthia Bernitsas
View Times: 111
Revisions: 2 times (View History)
Update Date: 22 Jan 2024
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback